D
Daniel F. Martin
Researcher at Emory University
Publications - Â 66
Citations - Â 5503
Daniel F. Martin is an academic researcher from Emory University. The author has contributed to research in topics: Retinitis & Vitrectomy. The author has an hindex of 36, co-authored 66 publications receiving 5265 citations. Previous affiliations of Daniel F. Martin include Duke University & International AIDS Society.
Papers
More filters
Journal ArticleDOI
Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant
Daniel F. Martin,Baruch D. Kuppermann,Richard A. Wolitz,Alan G. Palestine,Hong Li,Charles A. Robinson +5 more
TL;DR: In patients with AIDS and cytomegalovirus retinitis, oral ganciclovir in conjunction with a gancIClovir implant reduces the incidence of new cytomeGalovirus disease and delays progression of the retinopathy.
Journal ArticleDOI
Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.
Glenn J. Jaffe,Daniel F. Martin,David Callanan,P. Andrew Pearson,Brian Levy,Brian Levy,Timothy L. Comstock +6 more
TL;DR: The FA implant significantly reduced uveitis recurrences, improved VA, and decreased the need for adjunctive therapy in the studied patient population.
Journal ArticleDOI
Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration
Daniel F. Martin,Michael L. Klein,Julia A. Haller,Anthony P. Adamis,Evangelos S. Gragoudas,Joan W. Miller,Mark Blumenkrantz,Morton F. Goldberg,Lawrence A. Yannuzzi,Dwight Henninger,Laurie B. Wiegand,Long Shiuh Chen,Daniel W. Drolet,Stanley C. Gill,Jerry Bill,Blake Tomkinson,Raymond A. Bendele,Denis O'Shaughnessy,David R. Guyer,David R. Guyer,Samir C. Patel +20 more
TL;DR: This report is the first to describe administration of anti-VEGF therapy in humans for exudative macular degeneration and shows the safety of such therapy for single injections and larger studies are needed to prove the efficacy of this novel, potentially therapeutic agent for neovascular AMD.
Journal ArticleDOI
Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results
David R. Guyer,Gary E. Fish,Julia A. Haller,Allen C. Ho,Michael L. Klein,John I. Loewenstein,Daniel F. Martin,David H. Orth,Richard B Rosen,SR Sanislo,Steven D. Schwartz,Lawrence J. Singerman,George A. Williams +12 more
TL;DR: Anti-VEGF therapy is a promising treatment for various forms of ocular neovascularization, including AMD, and multiple intravitreal injections of the anti-VE GF aptamer were well tolerated in this phase II study.
Journal ArticleDOI
A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.
Daniel F. Martin,Juan Sierra-Madero,Sharon Walmsley,Richard A. Wolitz,Katherine Macey,Panos Georgiou,Charles A. Robinson,Mary Jean Stempien +7 more
TL;DR: Orally administered valganciclovIR appears to be as effective as intravenous ganciclovir for induction treatment and is convenient and effective for the long-term management of cytomegalovirus retinitis in patients with AIDS.